Enveric Biosciences Reports Director and Officer Changes in 8-K Filing

Enveric Biosciences, Inc. (ENVB) reported the departure of one director and the election of a new principal officer, according to an 8-K filed with the SEC on May 29, 2026.

The filing, submitted under Items 5.02, 5.07 and 9.01, covers both leadership transitions and the submission of matters to a vote of security holders. Item 5.02 requires disclosure of any departure or election of directors or principal officers, including the name of the individual, the position involved, the effective date and any cited cause.

Operationally the company moves from its prior board and executive roster to a revised structure. The new officer assumes their role on the effective date listed in the filing, while the departing director ceases service on the same date. The company must now update its governance disclosures in subsequent SEC filings, including its next Form 10-Q or 10-K, to reflect the current composition of the board and its committees.

Downstream, the leadership change requires the company to evaluate any impact on its audit, compensation or nominating committees and to determine whether any new director independence questions arise under Nasdaq or SEC rules. The filing also obligates Enveric to furnish any related board resolutions or employment agreements as exhibits under Item 9.01, which become part of the permanent public record.

Security holders who voted on the matters reported in Item 5.07 will see the outcome reflected in the company's proxy-statement follow-on disclosures.

This 8-K constitutes the official record of the corporate action for a non-watchlist public company whose shares trade under the ticker ENVB. The filing follows standard SEC practice that any material change in directors or executive officers must be reported within four business days.